Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

More documents

Recommendations

Info

International Experience• In 1992, Australia became the first country to formalise and issue mandatoryguidelines for health economics evaluations of pharmaceutical products as arequirement prior to reimbursement• Currently more than 32 guidelines around the world•Most experience relates to pharmaceuticals, although some countries havecentral programmes for evaluating (e.g. The Netherlands, UK).•The scope of requirements differs from place to place:All new drugs (Australia, Canada, Scotland),Drugs where a premium price is requested (the Netherlands )Drugs with a major impact (England and Wales, Portugal )
International ExperienceReimbursement/ ListingPurposeMethodological StandardsSourceGovernment/Payers BelgiumCanada (2 provinces)LDI Task Force (USA)Rovira et al(Spain)FinlandHungaryIrelandThe NetherlandsHannover (Germany)BESPE (Belgium)BMJ Working Party (UK)Garattini et al(Italy)New ZealandCollege of Economists (France)NorwayPortugalSwedenUnited KingdomAcademiaLangley et al (USA)PHrMA (USA)Alban et al (DK)IndustryPHrMA (USA)
Page 1 and 2: Proposed Pharmacoeconomics Guidelin
Page 3 and 4: Situations where economic evaluatio
Page 5: International Experiencee • Sever
Page 9 and 10: Why do guidelines differ?• Some i
Page 11 and 12: Primary AudienceSaudi decision and
Page 13 and 14: Standard Reporting Format• A stru
Page 16 and 17: Executive Summary• The Executive
Page 18 and 19: 2. BACKGROUND• General comments o
Page 20 and 21: 4. METHODS4.1 Perspective- State an
Page 22 and 23: 4. METHODS cont.4.6 Outcome measure
Page 24 and 25: 4. METHODS cont.4.8 Modelling- Econ
Page 26 and 27: 4. METHODS cont.4.10 Time horizon-
Page 28 and 29: 5. RESULTS cont5.2 Results of varia
Page 30 and 31: 7. CONCLUSIONS• Address the resea

Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?